Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen [...]
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Xencor finally finds buyer for onetime lead drug, offloading autoimmune [...]
New insights into how cancer cripples immune cells could fuel fresh I-O approaches
New insights into how cancer cripples immune cells could fuel [...]
Enanta dumps oral hep B program after safety warnings in early test
Enanta dumps oral hep B program after safety warnings in [...]
Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover preclinical cancer prospects
Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover [...]
Merck pauses ‘very important’ HIV program after seeing red flag in phase 2 trial of once-weekly combo
Merck pauses ‘very important’ HIV program after seeing red flag [...]
Personalized T cells could offer an immunotherapy option to children with brain tumors
Personalized T cells could offer an immunotherapy option to children [...]
J&J previews $60B-a-year future with plans to go after viruses that have long evaded vaccine makers
J&J previews $60B-a-year future with plans to go after viruses [...]
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Novo Nordisk bets big on RNAi, paying $3.3B to buy [...]
Gilead hits go on a host of Arcus cancer programs but forgoes rumored buyout in a $725M pact as TIGIT leads the way
Gilead hits go on a host of Arcus cancer programs [...]